Loading stock data…
BWAY
$16.84+0.28 (+1.69%)
Market ClosedLast close May 1
BrainsWay Ltd.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BrainsWay Ltd. in the Healthcare sector is trading at $16.84. The stock is currently near its 52-week high of $16.95, remaining 70.6% above its 200-day moving average. Technical signals show overbought RSI of 71 and bullish MACD crossover, explaining why BWAY maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 71) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$16.84
Potential Downside
82.9%
Whystock Fair Value$2.88
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of majo...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$635.81M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
88.06
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-14.79%
Volume
Today's trading volume
86,018
Recent News
Recent Price Trend in Brainsway (BWAY) is Your Friend, Here's Why
Brainsway (BWAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Zacks Industry Outlook Highlights Phibro Animal Health, BioLife Solutions, Omeros and Brainsway
Medical Products stocks face tariff and cost pressures, but Phibro Animal Health and peers leverage innovation, AI and demand trends to drive growth.
4 Medical Product Stocks to Buy From a Challenging Industry
The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.
Exploring Three Undiscovered Gems in the Middle East Market
The Middle East market has recently seen a positive uptick, with Gulf bourses closing higher amid hopes for renewed U.S.-Iran peace talks, which have bolstered investor sentiment across the region. In this environment of optimism and easing regional tensions, identifying promising stocks involves looking for companies with strong domestic fundamentals and resilience to geopolitical fluctuations.
Are Medical Stocks Lagging Alcon (ALC) This Year?
Here is how Alcon (ALC) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.